Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017

Minkook Son, Jeongkuk Seo, Sung Yang

1 Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea, 2 Department of Internal Medicine, Armed Forces Goyang Hospital, Goyang-si, Republic of Korea, 3 School of Mechanical Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea

☯ These authors contributed equally to this work.
* syang@gist.ac.kr

Abstract

Objectives
Despite the growing pieces of evidence linking hyperuricemia with metabolic syndrome and cardiovascular disease, the relationship between dyslipidemia and serum uric acid has not yet been established. This study aimed to investigate the association between individual components of dyslipidemia and serum uric acid by using the nationally representative Korea National Health and Nutrition Examination Survey 2016–2017.

Methods
A total of 8,722 participants (age ≥ 19 years) without missing values were analyzed for this study. Serum uric acid levels according to the presence of individual dyslipidemia components were calculated using multivariable-adjusted general linear models (GLM). Odds ratios of individual dyslipidemia components to hyperuricemia were calculated using unadjusted and multivariable-adjusted logistic regression analysis.

Results
A total of 1,061 participants were identified as having hyperuricemia, with a prevalence of 12.2%. Multivariable-adjusted GLM demonstrated a significant trend between individual dyslipidemia components and serum uric acid levels (P < 0.05). A positive association between the numbers of dyslipidemia components and the increments of serum uric acid levels was also observed (P < 0.001). In multivariable-adjusted logistic regression analysis, odds ratios (OR) and 95% confidence interval (CI) of all dyslipidemia components to hyperuricemia were shown to be statistically significant (P < 0.05). When further adjusted for the combined components themselves, each 10 mg/dL increments of total cholesterol (OR...
1.053; 95% CI 1.028–1.079), triglycerides (OR 1.017; 95% CI 1.009–1.026) and HDL-C (OR 0.804; 95% CI 0.729–0.887), retained significant correlation with hyperuricemia.

**Conclusion**

Our study demonstrated that the dyslipidemia components of serum total cholesterol, triglycerides and LDL-C levels are positively associated with serum uric acid levels, whereas serum HDL-C levels are inversely related. Further complementary studies regarding other lipid parameters are needed to confirm the accurate association between dyslipidemia and serum uric acid levels.

**Introduction**

Serum uric acid levels are known to be strongly linked with stroke [1], coronary artery disease [2] as well as hypertension [3] and metabolic syndrome [4]. However, the definite role of serum uric acid in these diseases is not yet established, due to its association with numerous other risk factors such as diet, obesity and dyslipidemia [5]. Emerging shreds of evidence show a rapidly increasing the prevalence of hyperuricemia in the international communities [6, 7], calling for investigations on the impact of serum uric acid in the pathogenesis and the prevalence of cardiovascular disease and metabolic syndrome.

Although the risk factors for metabolic syndrome and cardiovascular disease are being thoroughly studied, only a few studies to date have linked dyslipidemia to serum uric acid, including those investigated with the adult population of Bangladeshi [8], India [9], Italy [10], China [11], and USA [5]. However, despite the high prevalence (11.4%) of hyperuricemia in Korean population [12], information is lacking on the association of dyslipidemia with serum uric acid within the community. Considering the results of the aforementioned studies being insufficiently adjusted for the various laboratory & clinical confounders, in this study, we aimed to investigate the independent relationship between individual components of dyslipidemia and serum uric acid, with extensive adjustments for possible confounders, using the representative datasets of the Korean population.

**Materials and methods**

**Study population**

This study analyzed data from the seventh Korea National Health And Nutrition Examination Survey (KNHANES VII; 2016–2017) [13]. The KNHANES is a cross-sectional survey and a nationally representative database for Korean population, controlled by the Korea Centers for Disease Control and Prevention (KCDC). The survey uses a stratified multi-stage probability sampling method. KNHANES consists of health interviews, health examinations and nutritional surveys. Further information regarding study design and data variables can be found on the relevant website [14]. From the total number of 16,277 participants in KNHANES VII, 8,722 (male 3,704 [42.4%]) participants over the age of 19 without missing values were analyzed for this study. More information about participants and study design can be found in Fig 1.

Informed consent was obtained from all participants for voluntary participation and the KNHANES was approved by the Institutional Review Board of KCDC. The protocol of this study was approved by the Institutional Review Board of Gwangju Institute of Science and
Technology (20190705-EX-01-02), which waived the requirement for informed consent in regard to the anonymized data analyzed retrospectively. This study was performed based on the Declaration of Helsinki.

Demographic characteristics and survey on the status of lifestyle

Demographic data and medical history were obtained from self-reported questionnaires and personal interviews with trained staff. Level of education was divided into elementary school graduates or lower, middle school graduates, high school graduates, and college graduates or higher. Status regarding smoking was divided into 3 groups: (a) having smoked more than 5 packs of cigarettes and current smoking was defined as ‘current smokers’, (b) having smoked more than 5 packs of cigarettes and current non-smoking was defined as ‘ex-smokers’, and (c) those with less than 5 packs of cigarette smoking as ‘never smokers’. Alcohol consumption status was divided into 2 groups which are as follows: (a) ‘non-alcohol consumer’ with no alcohol consumption for the past year or consumption less than once a month, and (b) ‘alcohol consumer’ with alcohol consumption more than once a month. In regard to physical exercise, subjects were categorized into 2 groups: (a) ‘regular exercise’ group engaging in ≥ 150 minutes of moderately hard exercise per week or in ≥ 75 minutes of hard exercise per week or mixed exercise equivalent to the above level (1 minute of hard exercise equivalent to 2 minutes of moderately hard exercise) and (b) ‘non-regular exercise’ group with activity less than aforementioned level.

Anthropometric and laboratory measurements

Height and body weight were measured by a standardized protocol and body mass index (BMI) were calculated using weight (kg) per square of height (m²). Waist circumference was defined as the circumference measured at the midline of lower rib margin to iliac crest. Blood pressure was measured 3 times by trained nurses using a mercury sphygmomanometer.
Baumanometer, WA Baum Co., NY, USA) in a seated position with arm supported at heart level after 5 minutes of rest. All participants fasted for at least 8 hours before blood sampling. The samples were processed immediately and then refrigerated for transportation to the NeoDin Medical Institute (Seoul, Korea). All laboratory measurements were performed by the NeoDin Medical Institute. Further information for laboratory measurements can be found on the relevant website [14]. The Friedewald formula was used for the calculation of low density lipoprotein cholesterol (LDL-C) [15]. If triglyceride was over 400 mg/dL, values of direct measurement for LDL cholesterol levels were used. Non high density lipoprotein cholesterol (Non-HDL-C) is calculated as total cholesterol minus HDL-C [16]. Estimated glomerular filtration rate (eGFR) were calculated using the modification of diet in renal disease (MDRD) equation [17].

Definition of clinical variables
Hypertensive status was categorized into 3 groups: (a) 'hypertension' for systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg or on anti-hypertensive medication, (b) 'pre-hypertensive' for 120 mmHg ≤ SBP < 140 mmHg or 80 mmHg ≤ DBP < 90 mmHg, (c) and 'normal' for SBP < 120 mmHg and DBP < 80 mmHg. Diabetic status was categorized into 3 groups: (a) 'diabetes' for fasting blood sugar (FBS) ≥ 126 mg/dL or diagnosed or on medication for diabetes, (b) 'pre-diabetes' for 100 mg/dL ≤ FBS < 126 mg/dL, (c) and 'normal' for FBS < 100 mg/dL. Status regarding hypercholesterolemia, hypertriglyceridemia, low HDL-C and high LDL-C were categorized into 2 groups using criteria for the diagnosis of dyslipidemia in Koreans [18] and the cut-off values were designated as ≥ 240 mg/dL, ≥ 200 mg/dL, ≤ 40 mg/dL and ≥ 160 mg/dL respectively. Additionally, high level of non-HDL-C was set as ≥ 160 mg/dL [16]. Hyperuricemia was defined as serum uric acid level ≥ 7.0 mg/dL in men and ≥ 6.0 mg/dL in women [19].

Statistical analysis
Statistical procedures were conducted to reflect the complex sampling design and sampling weights of KNHANES VII. Data for continuous variables are presented as weighted means ± standard errors (SE) and data for categorical variables are presented as the number of cases with a weighted percentage. Characteristics of the participants with hyperuricemia were compared with those of participants without hyperuricemia using two independent sample Student’s t-tests for continuous variables and Chi-square test for categorical variables. The serum uric acid levels according to the presence of dyslipidemia were calculated using general linear models (GLM) with adjustments for multiple confounders and were compared by Bonferroni methods. Additionally, considering the differing serum uric acid levels between both gender, serum uric acid levels were calculated using GLM with the stratification of male and female groups. Unadjusted and multivariable-adjusted logistic regression analysis between each dyslipidemia components and hyperuricemia were performed. For multivariable-adjusted analysis, 4 models with progressive degrees of adjustment were utilized. Model 1 was adjusted for age and sex. Model 2 was further adjusted for age, sex and BMI. Model 3 was adjusted for age, sex, BMI, waist circumference, hemoglobin, blood urea nitrogen (BUN), glomerular filtration rate (GFR), hypertension, diabetes, smoking status, intake of alcohol and regular exercise, with model 4 further adjusted for the administration of dyslipidemia medication. All statistical analyses were performed with the complex sample procedures of SPSS software version 20 (IBM, SPSS Inc., NY, USA), and graphs in this study were drawn by Excel 2016 (Microsoft, USA). The p-value < 0.05 was considered to be statistically significant.
Table 1. Characteristics of participants by the presence of hyperuricemia.

| Total (n = 8,722) | Without hyperuricemia (n = 7,661) | With hyperuricemia (n = 1,061) | p-value* |
|------------------|----------------------------------|-------------------------------|---------|
| Age (years)      | 47.72 ± 0.32                     | 45.39 ± 0.64                  | < 0.001 |
| Sex (male)       | 2,986 (43.9)                     | 718 (74.9)                    | < 0.001 |
| Education (n)    |                                  |                               | 0.064   |
| elementary school or lower | 1,703 (15.9) | 219 (12.9)                  |         |
| middle school    | 771 (9.0)                        | 108 (8.3)                     |         |
| high school      | 2,320 (33.3)                     | 339 (33.8)                    |         |
| college or higher| 2,867 (41.8)                     | 395 (43.0)                    |         |
| BMI (kg/m²)      | 23.62 ± 0.06                     | 25.89 ± 0.14                  | < 0.001 |
| Waist circumference (cm) | 81.25 ± 0.18     | 88.39 ± 0.37                  | < 0.001 |
| SBP (mmHg)       | 116.90 ± 0.26                    | 121.59 ± 0.59                 | < 0.001 |
| DBP (mmHg)       | 75.18 ± 0.16                     | 78.93 ± 0.44                  | < 0.001 |
| Hemoglobin (g/dL)| 14.07 ± 0.02                     | 14.92 ± 0.06                  | < 0.001 |
| BUN (mg/dL)      | 13.77 ± 0.06                     | 15.21 ± 0.19                  | < 0.001 |
| GFR (mL/min/1.73m²)| 97.17 ± 0.32               | 87.44 ± 0.69                  | < 0.001 |
| Fasting glucose (mg/dL) | 98.95 ± 0.33    | 100.29 ± 0.67                 | 0.053   |
| hs-CRP (mg/L)    | 1.15 ± 0.03                      | 1.62 ± 0.08                   | < 0.001 |
| Serum uric acid (mg/dL) | 4.75 ± 0.01         | 7.52 ± 0.03                   | < 0.001 |
| Total cholesterol (mg/dL) | 192.63 ± 0.51       | 201.95 ± 1.61                 | < 0.001 |
| Triglycerides (mg/dL) | 125.66 ± 1.32      | 198.12 ± 9.30                 | < 0.001 |
| HDL-C (mg/dL)    | 52.23 ± 0.18                    | 46.03 ± 0.41                  | < 0.001 |
| LDL-C (mg/dL)    | 115.71 ± 0.45                   | 119.54 ± 1.17                 | 0.002   |
| Non-HDL-C (mg/dL)| 140.40 ± 0.50                   | 155.92 ± 1.60                 | < 0.001 |
| Numbers of dyslipidemia components |                |                               | < 0.001 |
| 0                | 5,153 (68.4)                     | 459 (43.4)                    |         |
| 1                | 1,418 (17.9)                     | 294 (27.2)                    |         |
| 2                | 941 (11.7)                       | 243 (22.9)                    |         |
| 3 or more        | 149 (2.1)                        | 65 (6.5)                      |         |
| Dyslipidemia medication | 958 (10.1)             | 113 (8.3)                     | 0.102   |
| Hypertension     | 2,321 (25.4)                     | 484 (39.3)                    | < 0.001 |
| Diabetes         | 951 (10.3)                       | 158 (10.9)                    | < 0.001 |
| Current smoker   | 1,177 (18.5)                     | 301 (32.6)                    | < 0.001 |
| Alcohol consumption | 3,980 (56.8)       | 677 (69.0)                    | < 0.001 |
| Regular Exercise | 3,384 (47.4)                     | 492 (51.3)                    | 0.037   |

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; BUN, blood urea nitrogen; GFR, Glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

Data are expressed as the weighted mean ± standard error or weighted percent (%).

* p-values are calculated by Student’s t-test for continuous variables and Chi-square test for categorical variables.

https://doi.org/10.1371/journal.pone.0228684.t001

Results

Demographic characteristics of study participants

The baseline characteristics of study participants according to the presence of hyperuricemia are summarized in Table 1. Among a total of 8,722 participants, 1,061 participants were identified as the hyperuricemia group (prevalence 12.2%, uric acid level designated as ≥ 7 mg/dL in men, ≥ 6 mg/dL in women) whereas 7,661 participants were assigned to non-hyperuricemia group. Compared with non-hyperuricemia group, sexual proportion (male to female); BMI; waist circumference; SBP and DBP; hemoglobin; BUN; GFR; high sensitivity C-reactive
protein; and serum uric acid levels tended to be elevated in the hyperuricemia group whereas average age tended to be lower. Total cholesterol, triglycerides, LDL-C and non-HDL-C levels were elevated with hyperuricemia whereas serum HDL-C levels were decreased. Participants with increased cumulative numbers of dyslipidemia components were significantly prevalent in the hyperuricemia group ($P < 0.001$). History of hypertension; diabetes; current smoking status; intake of alcohol; and regular exercise were also reported to be more frequent in the hyperuricemia group ($P < 0.05$).

**Association between the individual components of dyslipidemia and serum uric acid levels**

Fig 2 represents the association between the individual components of dyslipidemia and serum uric acid levels in the whole participants group: (A) Total cholesterol (B) Triglyceride (C) HDL-C (D) LDL-C. After adjusting for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, hypertension, diabetes, smoking status, intake of alcohol, regular exercise and the administration of dyslipidemia medication (model 4), serum uric acid levels showed positive trend (or negative trend with HDL-C) within each components of dyslipidemia ($P < 0.001$) with the exception of LDL-C ($P = 0.021$). The analysis of non-HDL-C with hyperuricemia also showed consistent results of positive relationship, as presented in S1 Table ($P < 0.001$). When the analysis was further stratified according to sex, a more evident trend could be observed in the male group (S1 Fig).

The association between the increasing number of dyslipidemia components and serum uric acid levels is presented in Fig 3(A). For the all participants group, adjusted serum uric acid levels showed a tendency to increase concomitantly with the increasing number of dyslipidemia components, with each comparison statistically significant except with the one between components of two and three or more ($P = 0.729$).

Fig 3(B) shows the subgroup comparison of adjusted serum uric acid levels between the dyslipidemia medication administered group and the group without the administration of dyslipidemia medication. Since the groups were analyzed with regard to the administration of dyslipidemia medication, adjustments were performed with model 3. The results show that the uric acid level in the medication administrated group was significantly lower in the categories of one dyslipidemia component and the three or more dyslipidemia components ($P < 0.05$, $P < 0.001$, respectively).

**Relationship between the individual components of dyslipidemia and hyperuricemia**

Table 2 presents the multivariable logistic regression analysis between the individual components of dyslipidemia and hyperuricemia in the all participants group. Odds ratios (OR) and 95% confidence interval (CI) of hyperuricemia to each of hypercholesterolemia, hypertriglyceridermia, HDL-C, and LDL-C levels were calculated. When adjusted for model 4, OR of all dyslipidemia components to hyperuricemia were shown to be statistically significant. For each 10 mg/dL increments of individual dyslipidemia components, the calculated OR for hyperuricemia retained statistical significance. Since LDL-C has a possibility for multicollinearity with other components due to the Friedewald formula, the further analysis takes into account only the total cholesterol levels, triglycerides and HDL-C levels. Individual components of hypercholesterolemia (OR 1.053; 95% CI 1.028–1.079, $P < 0.001$), hypertriglyceridermia (OR 1.017; 95% CI 1.009–1.026, $P < 0.001$) and HDL-C (OR 0.804; 95% CI 0.729–0.887, $P < 0.001$) retained significant correlations with hyperuricemia when further adjusted for the components combined (Table 3). Additionally, when non-HDL-C was replaced with total cholesterol,
non-HDL-C (OR 1.050; 95% CI 1.023–1.077, \( P < 0.001 \)) showed a significant correlation with hyperuricemia (S1 Table). The same analysis was made for the increasing numbers of dyslipidemia components, with the ORs of each cumulative numbers of one, two and three or more components statistically significant compared with the reference value of no dyslipidemia components (Table 3).

**Discussion**

Our analysis of 8,722 participants from the KNHANES VII survey suggests that there is a significant relationship between the individual components of dyslipidemia and the serum uric
To the best of our knowledge, this is the first large-scale study that reports the strong association between the two factors in a nationally representative sample of Korean adults.

Several important implications can be drawn from the present study. First, total cholesterol, triglycerides, LDL-C and non-HDL-C levels were positively associated with serum uric acid levels. Second, there was an inverse relationship between HDL-C levels and serum uric acid. These relationships remained significant regardless of adjustment for known risk factors and confounding variables including age, sex, BMI and others. Third, when the analysis was further stratified according sex, a more evident trend of association could be observed in the male participants group. Fourth, the increasing numbers of dyslipidemia components have shown to be positively associated with serum uric acid levels. Fifth, a recognizable trend of lower serum uric acid levels was observed in the group administered with dyslipidemia medication, compared with serum uric acid levels in the non-administered group.

Hyperuricemia is now considered to be an important risk factor for hypertension, metabolic syndrome, chronic kidney disease and cardiovascular disease [20]. Serum uric acid, previously known to have a beneficial effect as an oxygen radical scavenger [21], is now recognized to carry a vital role as the modulator of glucose and lipid metabolism [22], leading to observations that the breach of serum uric acid homeostasis may be associated with cardiovascular risk and all-cause mortality [22–24]. Current studies demonstrate the possibility of serum uric acid level as a predictor of incident metabolic syndrome [25] and, when combined with LDL-C, of incident hypertension [26]. However, the independent role of serum uric acid as a novel risk factor and a target for treatment regardless of the clinical history of gout has been a subject of debate. Despite growing pieces of evidence, consensus on whether the treatment of asymptomatic hyperuricemia would be beneficial or not is yet to be established [22, 23, 27, 28].

In the present study, individual dyslipidemia components showed a statistically significant correlation with hyperuricemia even after adjusting for multiple laboratory & clinical
confounders. Similar observations have been made in three previous cross-sectional studies [5, 8]. In the study by Peng et al., the serum LDL-C levels, triglycerides, total cholesterol, apolipoprotein-B levels, ratio of triglycerides to HDL-C and ratio of apolipoprotein-B to apolipoprotein-A1 were significantly associated with serum uric acid levels, whereas serum HDL-C levels were inversely associated [5]. The study by Ali et al. showed similar results to the aforementioned study with apolipoprotein-B and apolipoprotein-A1 not included in the data set [8]. Also, a study by Xu et al. has demonstrated that the parameter of non-HDL-C, along with triglycerides, is associated with hyperuricemia [29]. Our analysis has shown consistent results with the above findings.

The more distinct trend of male participants in the association between dyslipidemia and serum uric acid levels is worth noting. Studies to date have shown controversial results regarding whether gender differences mediate the association. A study by Stelmach et al. on Polish adults with hyperuricemia showed that the triglyceride values were higher in the upper tertile of serum uric acid levels in males but not in females [30]. A retrospective study by Lippi et al. demonstrated contradicting results, showing associations between triglycerides and serum

| Table 2. Multivariable logistic regression analysis between the components of dyslipidemia and hyperuricemia. |
|----------------------------------------------------------|
| **Case** | **Crude** | **Model 1** | **Model 2** | **Model 3** | **Model 4** |
|-----------|-----------|-------------|-------------|-------------|-------------|
| **Total cholesterol** | | | | | |
| < 240 mg/dL | 7,756 | 1 | 1 | 1 | 1 |
| ≥ 240 mg/dL | 966 | 1.686 | 1.367, 2.078 | < 0.001 | 1.835 | 1.480, 2.276 | < 0.001 | 1.619 | 1.300, 2.017 | < 0.001 | 1.503 | 1.191, 1.897 | < 0.001 | 1.455 | 1.152, 1.837 | 0.002 |
| **Total cholesterol (10 mg/dL)** | 8,722 | 1.069 | 1.046, 1.093 | < 0.001 | 1.08 | 1.057, 1.104 | < 0.001 | 1.064 | 1.041, 1.088 | < 0.001 | 1.064 | 1.040, 1.088 | < 0.001 | 1.059 | 1.035, 1.085 | < 0.001 |
| **Triglycerides** | | | | | |
| < 200 mg/dL | 7,437 | 1 | 1 | 1 | 1 |
| ≥ 200 mg/dL | 1,285 | 3.438 | 2.915, 4.054 | < 0.001 | 2.814 | 2.365, 3.349 | < 0.001 | 2.264 | 1.894, 2.705 | < 0.001 | 2.182 | 1.788, 2.664 | < 0.001 | 2.154 | 1.763, 2.632 | < 0.001 |
| **Triglycerides (10 mg/dL)** | 8,722 | 1.043 | 1.034, 1.052 | < 0.001 | 1.035 | 1.026, 1.044 | < 0.001 | 1.027 | 1.020, 1.035 | < 0.001 | 1.028 | 1.020, 1.036 | < 0.001 | 1.028 | 1.020, 1.036 | < 0.001 |
| **HDL-C** | | | | | |
| ≤ 40 mg/dL | 7,067 | 1 | 1 | 1 | 1 |
| > 40 mg/dL | 1,655 | 0.39 | 0.335, 0.455 | < 0.001 | 0.479 | 0.409, 0.563 | < 0.001 | 0.578 | 0.490, 0.682 | < 0.001 | 0.597 | 0.501, 0.710 | < 0.001 | 0.605 | 0.508, 0.721 | < 0.001 |
| **HDL-C (10 mg/dL)** | 8,722 | 0.631 | 0.584, 0.681 | < 0.001 | 0.697 | 0.643, 0.755 | < 0.001 | 0.776 | 0.714, 0.843 | < 0.001 | 0.772 | 0.708, 0.842 | < 0.001 | 0.775 | 0.711, 0.845 | < 0.001 |
| **LDL-C** | | | | | |
| < 160 mg/dL | 7,878 | 1 | 1 | 1 | 1 |
| ≥ 160 mg/dL | 844 | 1.345 | 1.054, 1.717 | 0.017 | 1.57 | 1.214, 2.031 | 0.001 | 1.44 | 1.106, 1.876 | 0.007 | 1.384 | 1.045, 1.833 | 0.023 | 1.34 | 1.011, 1.777 | 0.042 |
| **LDL-C (10 mg/dL)** | 8,722 | 1.036 | 1.013, 1.060 | 0.002 | 1.05 | 1.025, 1.075 | < 0.001 | 1.035 | 1.010, 1.060 | 0.005 | 1.037 | 1.012, 1.063 | 0.003 | 1.031 | 1.005, 1.057 | 0.02 |

OR, odds ratio; CI, confidence interval; BMI, body mass index; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HTN, hypertension; DM, diabetes; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

a Model 1: Adjusted for sex and age.
b Model 2: Adjusted for sex, age, and BMI.
c Model 3: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, and regular exercise.
d Model 4: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, regular exercise, and dyslipidemia medication.

https://doi.org/10.1371/journal.pone.0228684.t002
uric acid levels in women but not in men [10]. In this regard, the results of our study demonstrate positive association between triglycerides and serum uric acid levels in both male and female groups.

Further investigations in our study include the positive association between the increasing number of dyslipidemia components and the serum uric acid levels. Considering the above discussion on the relationship of individual dyslipidemia components with serum uric acid, our findings demonstrate that individual components of dyslipidemia collectively and individually associate with serum uric acid levels.

Our comparison between dyslipidemia medication administered and non-administered subgroups showed that although not coherent in the category of two dyslipidemia components, a trend of lower serum uric acid levels in the medication administered group can be recognized. This result is in line with previous studies relating to statin and fenofibrate therapy to the decrease of serum uric acid levels [31–33].

The current study has some limitations and restricting elements. The cross-sectional study design does not warrant us to draw cause-effect relationships between the dyslipidemia components and serum uric acid levels. Also, the nature of epidemiological study using surveys with established sets of variables was of significant restraint. The lack of data on other lipid parameters (lipoprotein(a), apolipoprotein-A1, apolipoprotein-B) other than the parameters covered in this study should be considered as a relevant limitation. Important factors, such as which medications of lipid lowering agents were used, participant history of gout and whether

| Table 3. Multivariable logistic regression analysis between dyslipidemia and hyperuricemia. |
|-----------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                              | Crude OR       | Model 1 * OR  | Model 2 * OR  | Model 3 * OR  | Model 4 * OR  |
|                                              | 95% CI        | 95% CI        | 95% CI        | 95% CI        | 95% CI        |
| Combined lipid profile                       | 8,722          | 1.064, 1.040, 1.087 | 1.07, 1.046, 1.096 | 1.053, 1.029, 1.078 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 |
| Total cholesterol (10 mg/dL)                 | 1.064, 1.040, 1.087 | 1.07, 1.046, 1.096 | 1.053, 1.029, 1.078 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 | 1.053, 1.028, 1.079 |
| Triglyceride (10 mg/dL)                      | 1.022, 1.013, 1.031 | 1.018, 1.009, 1.027 | 1.017, 1.009, 1.025 | 1.017, 1.009, 1.025 | 1.017, 1.009, 1.025 | 1.017, 1.009, 1.025 | 1.017, 1.009, 1.025 | 1.017, 1.009, 1.025 |
| HDL-C (10 mg/dL)                             | 0.675, 0.619, 0.737 | 0.728, 0.666, 0.796 | 0.806, 0.736, 0.883 | 0.804, 0.729, 0.887 | 0.804, 0.729, 0.887 | 0.804, 0.729, 0.887 | 0.804, 0.729, 0.887 | 0.804, 0.729, 0.887 |
| Number of dyslipidemia components            | 8,722          | 1.712, 2.389, 2.853 | 2.068, 1.724, 2.479 | 1.747, 1.446, 2.111 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 |
| 0                                             | 5,612          | 1.712, 2.389, 2.853 | 2.068, 1.724, 2.479 | 1.747, 1.446, 2.111 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 | 1.702, 1.389, 2.085 |
| 1                                             | 1,184          | 3.092, 2.552, 3.746 | 2.933, 2.394, 3.594 | 2.365, 1.926, 2.902 | 2.194, 1.751, 2.748 | 2.194, 1.751, 2.748 | 2.194, 1.751, 2.748 | 2.194, 1.751, 2.748 |
| 3 or more                                     | 214            | 4.99, 3.539, 7.038 | 4.228, 3.009, 5.940 | 3.096, 2.197, 4.364 | 2.903, 2.024, 4.165 | 2.903, 2.024, 4.165 | 2.903, 2.024, 4.165 | 2.903, 2.024, 4.165 |

OR, odds ratio; CI, confidence interval; BMI, body mass index; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HTN, hypertension; DM, diabetes; HDL-C, high density lipoprotein cholesterol.

* Model 1: Adjusted for sex and age.
* Model 2: Adjusted for sex, age, and BMI.
* Model 3: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, and regular exercise.
* Model 4: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, regular exercise, and dyslipidemia medication.

https://doi.org/10.1371/journal.pone.0228684.t003
urate lowering treatments were administered or not, weren’t included in the questionnaire, leading to insufficient data. However, considering the low prevalence of gout in the general Korean population (0.76%) [34], it is unlikely that the unavailable data regarding the clinical history of gout or the participants taking urate lowering agents significantly affected the results [12].

Whether serum uric acid is only a marker of preexisting disorder or a causal factor for dyslipidemia and cardiovascular disease remains controversial [5]. Regarding the relationship between serum uric acid and the lipoprotein metabolism, studies have shown that elevated serum uric acid is a significant predictor of smaller and denser LDL-C and HDL-C particles, which are known to be related with higher cardiovascular disease risk [35]. Although these previous studies and biological plausibility coherently support the results of this study, sufficiently powered prospective randomized clinical trials would be warranted for establishing causal relationships between the factors and for further applications into clinical practice.

**Conclusion**

After adjusting for potential confounders, our study demonstrated that the dyslipidemia components of serum total cholesterol, triglycerides and LDL-C levels are positively associated with serum uric acid levels, whereas serum HDL-C levels are inversely related. Further complementary studies regarding other lipid parameters are needed to confirm the accurate association between dyslipidemia and serum uric acid levels.

**Supporting information**

**S1 Fig. Adjusted serum uric acid levels in male & female group according to the individual dyslipidemia components.** (A) Total cholesterol (B) Triglyceride (C) HDL-C (D) LDL-C. Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, regular exercise and dyslipidemia medication (model 4). Error bars represent standard errors. Each number of asterisks corresponds to the following p-values. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

**S1 Table. Multivariable logistic regression analysis between non-HDL-C and hyperuricemia.** OR, odds ratio; CI, confidence interval; BMI, body mass index; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HTN, hypertension; DM, diabetes; HDL-C, high density lipoprotein cholesterol. a Model 1: Adjusted for sex and age. b Model 2: Adjusted for sex, age, and BMI. c Model 3: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, and regular exercise. d Model 4: Adjusted for age, sex, waist circumference, BMI, hemoglobin, BUN, GFR, HTN, DM, smoking, alcohol consumption, regular exercise, and dyslipidemia medication.

**Acknowledgments**

Data are available from the Korea National Health and Nutrition Examination Survey (KNHANES), conducted by the Korea Centers for Disease Control and Prevention (KCDCP), and are freely available from KCDCP (https://knhanes.cdc.go.kr).

**Author Contributions**

**Conceptualization:** Minkook Son, Jeongkuk Seo, Sung Yang.
Formal analysis: Minkook Son, Jeongkuk Seo.
Funding acquisition: Sung Yang.
Methodology: Minkook Son, Jeongkuk Seo.
Supervision: Sung Yang.
Validation: Minkook Son, Jeongkuk Seo.
Visualization: Minkook Son.
Writing – original draft: Minkook Son, Jeongkuk Seo.
Writing – review & editing: Minkook Son, Jeongkuk Seo.

References
1. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998; 29(3):635–9. Epub 1998/03/20. https://doi.org/10.1161/01.str.29.3.635 PMID: 9506605.
2. Bickel C, RHJ, Blankenberg S. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. The American Journal of Cardiology. 2002; 89(1):12–7. https://doi.org/10.1016/s0002-9149(01)02155-5 PMID: 11779515
3. Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014; 37(8):785–9. Epub 2014/03/29. https://doi.org/10.1038/hr.2014.75 PMID: 24671018.
4. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007; 120(5):442–7. Epub 2007/05/01. https://doi.org/10.1016/j.amjmed.2006.06.040 PMID: 17466556.
5. Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, et al. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int. 2015; 2015:127596. Epub 2015/01/30. https://doi.org/10.1155/2015/127596 PMID: 25629033; PubMed Central PMCID: PMC421757.
6. Ali N, Pereveen R, Rahman S, Mahmood S, Rahman S, Islam S, et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. PLoS One. 2018; 13(11):e0206850. Epub 2018/11/02. https://doi.org/10.1371/journal.pone.0206850 PMID: 30383816; PubMed Central PMCID: PMC621757.
7. Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015; 2015:762820. Epub 2015/12/08. https://doi.org/10.1155/2015/762820 PMID: 26640795; PubMed Central PMCID: PMC4657091.
8. Ali N, Rahman S, Islam S, Haque T, Molla NH, Sumon AH, et al. The relationship between serum uric acid and lipid profile in Bangladeshi adults. BMC Cardiovasc Disord. 2019; 19(1):42. Epub 2019/02/23. https://doi.org/10.1186/s12872-019-1026-2 PMID: 30791868; PubMed Central PMCID: PMC6385393.
9. Sarmah D, SB. A correlative study of uric acid with lipid profile. Asian Journal of Medical Sciences. 2013; 4:8–14.
10. Lippi G, Montagnana M, Luca Salvagno G, Targher G, Cesare Guidi G. Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile. Clin Cardiol. 2010; 33(2):E76–80. Epub 2010/01/01. https://doi.org/10.1002/clc.20511 PMID: 20043336.
11. Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019; 18(1):81. Epub 2019/04/03. https://doi.org/10.1186/s12944-019-1031-6 PMID: 30935401; PubMed Central PMCID: PMC6444567.
12. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018; 37(9):2529–38. Epub 2018/05/24. https://doi.org/10.1007/s10067-018-4130-2 PMID: 29790110.
13. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43(1):69–77. Epub 2014/03/04. https://doi.org/10.1093/ije/dyt228 PMID: 24585853; PubMed Central PMCID: PMC3937975.
14. Korea Centers for Disease Control and Prevention. The Korea National Health and Nutrition Examination Survey. https://knhanes.cdc.go.kr. 2019.
30. Stelmach MJ, Wasilewska N, Wicklund-Liland LI, Wasilewska A. Blood lipid profile and BMI-Z-score in 25.

25. Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, et al. Serum uric acid predicts 26.

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans 27.

against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981; 78(11):6858–62. Epub 1981/11/01. https://doi.org/10.1073/pnas.78.11.6858 PMID: 6947260; PubMed Central PMCID: PMC349151.

28. Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015; 116:17–23. Epub 2015/07/03. https://doi.org/10.1016/j.biochi.2015.06.025 PMID: 26139655.

29. Xu J, Peng H, Ma Q, Zhou X, Xu W, Huang L, et al. Associations of non-high density lipoprotein cholesteryl and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study. Lipids Health Dis. 2014; 13:117. Epub 2014/07/24. https://doi.org/10.1186/1747-511X-13-117 PMID: 25052552; PubMed Central PMCID: PMC4115491.

30. Stelmach MJ, Wasilewska N, Wicklund-Liland LI, Wasilewska A. Blood lipid profile and BMI-Z-score in adolescents with hyperuricemia. Ir J Med Sci. 2015; 184(2):463–8. Epub 2014/08/05. https://doi.org/10.1007/s11845-014-1146-8 PMID: 24876094.

31. Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Drugs. 2016; 76(9):947–56. Epub 2016/06/05. https://doi.org/10.1007/s40265-016-0591-2 PMID: 27260336.

32. Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018; 8(1):16767. Epub 2018/11/15. https://doi.org/10.1038/s41598-018-35175-z PMID: 30425304; PubMed Central PMCID: PMC6233215.

Association between dyslipidemia and serum uric acid levels in Korean adults
33. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004; 148(4):635–40. Epub 2004/10/02. https://doi.org/10.1016/j.ahj.2004.04.005 PMID: 15459594.

34. Kim JW, Kwak SG, Lee H, Kim SK, Choe JY, Park SH. Prevalence and incidence of gout in Korea: data from the national health claims database 2007–2015. Rheumatol Int. 2017; 37(9):1499–506. Epub 2017/07/06. https://doi.org/10.1007/s00296-017-3768-4 PMID: 28676911.

35. Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Memon L, Zejko A, Bogavic-Stanojevic N, et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis. 2009; 203(1):236–42. Epub 2008/07/08. https://doi.org/10.1016/j.atherosclerosis.2008.05.047 PMID: 18603253.